Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00914927 · ClinicalTrials.gov registry record · Phase 2
Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures
A Phase 2 study of Thrombocytopenia Related to Chronic Liver Disease, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 1
- Study location
NCT00914927 is a Phase 2 study of Thrombocytopenia Related to Chronic Liver Disease that has completed, run by Eisai. The registered enrollment target is 130 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00914927, a Phase 2 study of Thrombocytopenia Related to Chronic Liver Disease, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the efficacy of once-daily Oral avatrombopagin subjects with chronic liver diseases and thrombocytopenia prior to elective surgical or diagnostic procedures, to evaluate the safety of short-term administration of avatrombopag and to evaluate the pharmacokinetics (PK) of E5501.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Avatrombopag
Study Locations (1)
Louisiana
- Ochsner Clinic Foundation - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-12-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00914927
The ClinicalTrials.gov registry entry for NCT00914927 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thrombocytopenia Related to Chronic Liver Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00914927 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT00914927 about?
NCT00914927 is a clinical study titled "Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures". The purpose of this study is to evaluate the efficacy of once-daily Oral avatrombopagin subjects with chronic liver diseases and thrombocytopenia prior to elective surgical or diagnostic procedures, to evaluate the safety of short-term administration of avatrombopag and to evaluate the pharmacokinet...
What is the current status of trial NCT00914927?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2009-05. Estimated completion is 2011-12-21.
What conditions does trial NCT00914927 study?
This clinical trial studies the following conditions: Thrombocytopenia Related to Chronic Liver Disease.
What interventions are being tested in trial NCT00914927?
The interventions under investigation include: Placebo (DRUG), Avatrombopag (DRUG).
Who is sponsoring clinical trial NCT00914927?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00914927 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.